Target Information

Target General Infomation
Target ID
T21945
Former ID
TTDC00304
Target Name
Sodium-dependent noradrenaline transporter
Gene Name
SLC6A2
Synonyms
NET; Norepinephrine transporter; SLC6A2
Target Type
Successful
Disease Attention deficit hyperactivity disorder; Depression; Cocaine addiction [ICD9: 303-304, 304.2, 311, 314.00, 314.01; ICD10: F10-F19, F14.2, F32, F90]
Attention deficit hyperactivity disorder [ICD9: 314; ICD10: F90]
Attention deficit hyperactivity disorder; Severe mood disorders [ICD9: 296, 314.00, 314.01; ICD10: F30-F39, F90]
Anesthesia; Ocular disease [ICD9:338; ICD10: R20.0, H00-H59]
Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10: F01-F07, F04, F05, R41.3]
Cancer pain [ICD9: 140-229, 338,780; ICD10: R52, G89]
Chronic low back pain; Neuropathic pain [ICD9: 338, 356.0, 356.8, 724.2, 724.5,780; ICD10: G64, G90.0, M54, M54.5, R52, G89]
Depression; Attention deficit hyperactivity disorder [ICD9: 311, 314.00, 314.01; ICD10: F30-F39, F90]
Depression [ICD9: 311; ICD10: F30-F39]
Depression; Bipolar disorder [ICD9:311, 296.0, 296.1, 296.4, 296.5, 296.6, 296.7, 296.8, 300; ICD10: F30-F39, F31, F40-F42]
Depression; Chronic pain [ICD9: 311, 338,780; ICD10: F30-F39, R52, G89]
Depression; Attention deficit hyperactivity disorder [ICD9:311, 314; ICD10: F30-F39, F90]
Depression; Anxiety disorder [ICD9:311, 300; ICD10: F30-F39, F32, F40-F42]
Fibromyalgia [ICD9: 729.1; ICD10: M79.7]
Fatigue [ICD10: R53]
Glaucoma [ICD9: 365; ICD10: H40-H42]
Heart failure [ICD9: 428; ICD10: I50]
Heart failure diagnosis [ICD9: 428; ICD10: I50]
Moderate-to-severe acute pain [ICD9: 338,780; ICD10: R52, G89]
Mood disorder [ICD10: F30-F39]
Migraine; Obisity [ICD9: 278, 346; ICD10: E66, G43]
Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10: F32, F33, M32]
Neurological disease [ICD9: 338, 338.2, 410, 782.3,780; ICD10: I21, I22, R52, R52.1-R52.2, R60.9, G89]
Neuropathic pain [ICD9: 356.0, 356.8; ICD10: G64, G90.0]
Neuroendocrine cancer [ICD10: C7A]
Neuroblastoma [ICD9: 194.0, 194.5, 194.6, 227.0, 227.5, 227.6, 237.3, 255.6; ICD10: C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7]
Obesity [ICD9: 278; ICD10: E66]
Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89]
Smoking cessation [ICD9: 292; ICD10: F17.2]
Severe mood disorders [ICD9: 296; ICD10: F30-F39]
Unspecified [ICD code not available]
Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
BioChemical Class
Neurotransmitter:sodium symporter
Target Validation
T21945
UniProt ID
P23975
Sequence
MLLARMNPQVQPENNGADTGPEQPLRARKTAELLVVKERNGVQCLLAPRDGDAQPRETWG
KKIDFLLSVVGFAVDLANVWRFPYLCYKNGGGAFLIPYTLFLIIAGMPLFYMELALGQYN
REGAATVWKICPFFKGVGYAVILIALYVGFYYNVIIAWSLYYLFSSFTLNLPWTDCGHTW
NSPNCTDPKLLNGSVLGNHTKYSKYKFTPAAEFYERGVLHLHESSGIHDIGLPQWQLLLC
LMVVVIVLYFSLWKGVKTSGKVVWITATLPYFVLFVLLVHGVTLPGASNGINAYLHIDFY
RLKEATVWIDAATQIFFSLGAGFGVLIAFASYNKFDNNCYRDALLTSSINCITSFVSGFA
IFSILGYMAHEHKVNIEDVATEGAGLVFILYPEAISTLSGSTFWAVVFFVMLLALGLDSS
MGGMEAVITGLADDFQVLKRHRKLFTFGVTFSTFLLALFCITKGGIYVLTLLDTFAAGTS
ILFAVLMEAIGVSWFYGVDRFSNDIQQMMGFRPGLYWRLCWKFVSPAFLLFVVVVSIINF
KPLTYDDYIFPPWANWVGWGIALSSMVLVPIYVIYKFLSTQGSLWERLAYGITPENEHHL
VAQRDIRQFQLQHWLAI
Drugs and Mode of Action
Drug(s) Amfepramone Drug Info Approved Obesity [1]
Amitriptyline Drug Info Approved Depression; Chronic pain [2], [3], [4]
Amoxapine Drug Info Approved Major depressive disorder [5], [6], [4]
Atomoxetine Drug Info Approved Attention deficit hyperactivity disorder [7], [8]
Bupropion Drug Info Approved Smoking cessation [4]
Cocaine Drug Info Approved Anesthesia; Ocular disease [9], [10], [4]
Desipramine Drug Info Approved Depression; Attention deficit hyperactivity disorder [2], [11], [4]
Desvenalfaxine succinate Drug Info Approved Fibromyalgia [12]
Diethylpropion Drug Info Approved Migraine; Obisity [7], [13]
Duloxetine Drug Info Approved Depression [2], [14]
Imipramine Drug Info Approved Depression; Anxiety disorder [2], [15], [4]
Iobenguane I 123 injection Drug Info Approved Heart failure diagnosis [16], [4]
Iobenguane I-123 Drug Info Approved Neuroendocrine cancer [17]
Iobenguane I-123 - GE Healthcare Drug Info Approved Unspecified [4]
Levomilnacipran Drug Info Approved Fibromyalgia [18], [19]
Maprotiline Drug Info Approved Major depressive disorder [4]
Mazindol Drug Info Approved Obesity [20], [21]
Milnacipran Drug Info Approved Depression [22], [23]
Phenmetrazine Drug Info Approved Obesity [24]
Phentermine Drug Info Approved Obesity [25], [26]
Protriptyline Drug Info Approved Depression; Bipolar disorder [2], [27], [4]
Reboxetine Drug Info Approved Depression [28], [2]
Sibutramine Drug Info Approved Obesity [25], [29]
Tapentadol hydrochloride Drug Info Approved Moderate-to-severe acute pain [17]
Trimipramine Drug Info Approved Major depressive disorder [4]
Ultracet Drug Info Approved Pain [30]
Venlafaxine Drug Info Approved Depression [31], [32]
Hypericum Drug Info Phase 4 Discovery agent [33]
Amitifadine Drug Info Phase 3 Obesity [34], [35]
Bicifadine Drug Info Phase 3 Chronic low back pain; Neuropathic pain [36]
Bupropion+naltrexone Drug Info Phase 3 Obesity [37]
Dasotraline Drug Info Phase 3 Mood disorder [38], [39]
Roclatan Drug Info Phase 3 Glaucoma [40]
Suronacrine maleate Drug Info Phase 3 Cognitive disorders [41]
18F-LMI-1195 Drug Info Phase 2 Heart failure [42]
DOV 21947 Drug Info Phase 2 Severe mood disorders [22]
MCT-125 Drug Info Phase 2 Fatigue [43]
Metaiodobenzylguanidine I-131 Drug Info Phase 2 Neuroblastoma [44]
METHYLENEDIOXYMETHAMPHETAMINE Drug Info Phase 2 Discovery agent [45]
Rhopressa Drug Info Phase 2 Glaucoma [46]
TD-9855 Drug Info Phase 2 Pain [47]
XEN-2174 Drug Info Phase 2 Cancer pain [48]
BL-1021 Drug Info Phase 1 Pain [49]
GSK-1360707 Drug Info Phase 1 Major depressive disorder [50]
DOV-216303 Drug Info Discontinued in Phase 2 Severe mood disorders [22]
Esreboxetine Drug Info Discontinued in Phase 2 Fibromyalgia [51]
GSK372475 Drug Info Discontinued in Phase 2 Attention deficit hyperactivity disorder; Severe mood disorders [52]
Manifaxine Drug Info Discontinued in Phase 2 Major depressive disorder [53]
Napitane mesilate Drug Info Discontinued in Phase 2 Major depressive disorder [54]
NS 2359 Drug Info Discontinued in Phase 2 Attention deficit hyperactivity disorder; Depression; Cocaine addiction [22]
NS-2389 Drug Info Discontinued in Phase 2 Major depressive disorder [55]
R-sibutramine metabolite Drug Info Discontinued in Phase 2 Depression; Attention deficit hyperactivity disorder [22]
Radafaxine Drug Info Discontinued in Phase 2 Major depressive disorder [56]
SPD-473 Drug Info Discontinued in Phase 2 Mood disorder [57]
NSD-644 Drug Info Discontinued in Phase 1 Neurological disease [58]
Radaxafine HCl Drug Info Discontinued in Phase 1 Neuropathic pain [36]
RG-7166 Drug Info Discontinued in Phase 1 Major depressive disorder [59]
Inhibitor ((3R,4R)-4-(o-tolyloxy)chroman-3-yl)methanamine Drug Info [60]
(+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine Drug Info [61]
(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol Drug Info [62]
(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol Drug Info [62]
(R)-1-((S)-morpholin-2-yl)-1,2-diphenylethanol Drug Info [63]
(R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol Drug Info [64]
(R)-3-(naphthalen-2-ylmethoxy)pyrrolidine Drug Info [61]
(R)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile Drug Info [61]
(R)-DULOXETINE Drug Info [65]
(R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide Drug Info [66]
(R)-N-isopropyl-N-(pyrrolidin-3-yl)-2-naphthamide Drug Info [66]
(R)-Norfluoxetine Drug Info [67]
(S)-3-(naphthalen-2-ylmethoxy)pyrrolidine Drug Info [61]
(S)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile Drug Info [61]
(S)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide Drug Info [66]
(S)-NORDULOXETINE Drug Info [65]
(S)-Norfluoxetine Drug Info [67]
1-(1,2-diphenylethyl)piperazine Drug Info [68]
1-(1,4-diphenylbutan-2-yl)piperazine Drug Info [69]
1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) Drug Info [64]
1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) Drug Info [64]
1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine Drug Info [64]
1-(1-phenyl-2-o-tolylethyl)piperazine Drug Info [68]
1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamine Drug Info [70]
1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine Drug Info [71]
1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX) Drug Info [64]
1-(2-(2-bromophenyl)-1-phenylethyl)piperazine Drug Info [68]
1-(2-(2-chlorophenoxy)pyridin-3-yl)piperazine Drug Info [72]
1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine Drug Info [68]
1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine Drug Info [68]
1-(2-(2-ethylphenyl)-1-phenylethyl)piperazine Drug Info [68]
1-(2-(2-fluorobenzyloxy)phenyl)piperazine Drug Info [71]
1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine Drug Info [64]
1-(2-(3-chlorophenyl)-1-phenylethyl)piperazine Drug Info [68]
1-(2-(3-fluorophenoxy)phenyl)piperazine Drug Info [71]
1-(2-(3-methoxyphenyl)-1-phenylethyl)piperazine Drug Info [68]
1-(2-(4-fluorophenoxy)phenyl)piperazine Drug Info [71]
1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine Drug Info [61]
1-(2-(benzyloxy)phenyl)piperazine Drug Info [71]
1-(2-(phenoxymethyl)phenyl)piperazine Drug Info [71]
1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one Drug Info [73]
1-(2-phenoxyphenyl)piperazine Drug Info [71]
1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol Drug Info [74]
1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol Drug Info [74]
1-(3,4-dichlorophenyl)-3-aza-bicyclo[3.1.0]hexane Drug Info [75]
1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one Drug Info [76]
1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one Drug Info [76]
1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one Drug Info [76]
1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one Drug Info [73]
1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one Drug Info [73]
1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one Drug Info [76]
1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one Drug Info [73]
1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-one Drug Info [73]
1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one Drug Info [73]
1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one Drug Info [73]
1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one Drug Info [73]
1S,2R-milnacipran Drug Info [77]
2-((2-iodophenoxy)(phenyl)methyl)morpholine Drug Info [78]
2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine Drug Info [78]
2-(2'-Aminoethyl)-5-benzyltetrahydrofuran Drug Info [79]
2-(2,3-Dihydro-1H-indol-5-yl)-1-methyl-ethylamine Drug Info [70]
2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine Drug Info [72]
2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine Drug Info [72]
2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine Drug Info [72]
2-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile Drug Info [68]
2-(Aminomethyl)-5-(1'-naphthethyl)tetrahydrofuran Drug Info [79]
2-(Aminomethyl)-5-(1'-naphthyl)tetrahydrofuran Drug Info [79]
2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuran Drug Info [79]
2-(Aminomethyl)-5-phenethyltetrahydrofuran Drug Info [79]
2-(N,N-Diethylamino)-3'-chloropropiophenone Drug Info [80]
2-(N-Cyclopentylamino)-3'-bromopropiophenone Drug Info [76]
2-(N-Cyclopentylamino)-3'-chloropropiophenone Drug Info [80]
2-(N-Cyclopentylamino)-3'-fluoropropiophenone Drug Info [76]
2-(N-Cyclopentylamino)-3'-methoxypropiophenone Drug Info [76]
2-(N-Cyclopentylamino)-3'-methylpropiophenone Drug Info [76]
2-(N-Cyclopropylamino)-3-chloropropiophenone Drug Info [80]
2-(N-Pyrrolidinyl)-3'-bromopropiophenone Drug Info [76]
2-(N-Pyrrolidinyl)-3'-fluoropropiophenone Drug Info [76]
2-(N-Pyrrolidinyl)-3'-methoxypropiophenone Drug Info [76]
2-(N-Pyrrolidinyl)-3'-methylpropiophenone Drug Info [76]
2-(N-Pyrrolidinyl)-3'-nitropropiophenone Drug Info [76]
2-(N-tert-Butylamino)-3',4'-dichloropropiophenone Drug Info [80]
2-(N-tert-Butylamino)-3'-chloroheptanophenone Drug Info [80]
2-(N-tert-Butylamino)-3'-chlorohexanophenone Drug Info [80]
2-(N-tert-Butylamino)-3'-chlorooctanophenone Drug Info [80]
2-(N-tert-Butylamino)-3'-chloropentanophenone Drug Info [80]
2-(N-tert-Butylamino)propiophenone Drug Info [80]
2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one Drug Info [76]
2-(tert-butylamino)-1-m-tolylpropan-1-one Drug Info [76]
2-(tert-butylamino)-1-p-tolylpropan-1-one Drug Info [76]
2-(tert-Butylamino)-3',4'-dichlorobutyrophenone Drug Info [80]
2-(tert-Butylamino)-3',4'-dichloropentanophenone Drug Info [80]
2-Amino-1-(4-methylthiophenyl)propane Drug Info [81]
2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran Drug Info [79]
2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran Drug Info [79]
2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran Drug Info [79]
2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran Drug Info [79]
2-Aminomethyl-5-(phenyl)tetrahydrofuran Drug Info [79]
2-phenoxy-3-(piperidin-4-yl)pyridine Drug Info [72]
2pyrrolidin-1-yl-1-phenylpentan-1-one Drug Info [73]
3-(1H-indol-1-yl)-N-methyl-3-phenylpropan-1-amine Drug Info [82]
3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile Drug Info [68]
3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol Drug Info [68]
3-(3'-furyl)-aniline Drug Info [83]
3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine Drug Info [72]
3-p-Tolyl-8-aza-bicyclo[3.2.1]octane Drug Info [84]
3alpha-(bis-chloro-phenylmethoxy)tropane Drug Info [85]
4-((naphthalen-2-yloxy)methyl)piperidine Drug Info [61]
4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine Drug Info [86]
4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine Drug Info [71]
4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine Drug Info [71]
4-(2-(2-fluorobenzyloxy)phenyl)piperidine Drug Info [71]
4-(2-(3-chlorophenoxy)phenyl)piperidine Drug Info [71]
4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine Drug Info [71]
4-(2-(3-fluorophenoxy)phenyl)piperidine Drug Info [71]
4-(2-(4-fluorobenzyloxy)phenyl)piperidine Drug Info [71]
4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine Drug Info [71]
4-(2-(4-fluorophenoxy)phenyl)piperidine Drug Info [71]
4-(2-(benzyloxy)-3-fluorophenyl)piperidine Drug Info [71]
4-(2-(benzyloxy)-6-fluorophenyl)piperidine Drug Info [71]
4-(2-(benzyloxy)phenyl)piperidine Drug Info [71]
4-(2-(phenoxymethyl)phenyl)piperidine Drug Info [71]
4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine Drug Info [72]
4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine Drug Info [71]
4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine Drug Info [71]
4-(2-fluoro-6-phenoxyphenyl)piperidine Drug Info [71]
4-(2-phenoxyphenyl)piperidine Drug Info [71]
4-(3'-furyl)-aniline Drug Info [83]
4-(3-fluoro-2-phenoxyphenyl)piperidine Drug Info [71]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Drug Info [87]
6-(piperidin-4-ylmethoxy)-2-naphthonitrile Drug Info [61]
7-(piperidin-4-ylmethoxy)-2-naphthonitrile Drug Info [61]
8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane Drug Info [84]
Amfepramone Drug Info [1]
AMIFLAMINE Drug Info [70]
Amitifadine Drug Info [88]
Amitriptyline Drug Info [89], [90]
Amoxapine Drug Info [91]
Atomoxetine Drug Info [92], [93]
Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine Drug Info [94]
Bupropion Drug Info [95]
Bupropion+naltrexone Drug Info [25]
Cis-3-phenoxy-2,3-dihydro-1H-inden-1-amine Drug Info [96]
Cocaine Drug Info [97]
D-166A Drug Info [98]
D-211A Drug Info [98]
D-211B Drug Info [98]
D-254C Drug Info [98]
D-257A Drug Info [98]
D-257C Drug Info [98]
Dasotraline Drug Info [99]
Desipramine Drug Info [100]
Desvenalfaxine succinate Drug Info [12]
Diethylpropion Drug Info [101]
DIFLUOROBENZTROPINE Drug Info [85]
DOV 21947 Drug Info [22]
DOV-216303 Drug Info [22]
Duloxetine Drug Info [102], [103]
GSK-1360707 Drug Info [104]
GSK372475 Drug Info [22]
Hypericum Drug Info [105]
Imipramine Drug Info [106], [107]
Iobenguane I 123 injection Drug Info [17]
Iobenguane I-123 Drug Info [88]
Isobutyl-(4-methyl-benzyl)-piperidin-4-yl-amine Drug Info [108]
KF-A5 Drug Info [109]
Maprotiline Drug Info [110]
MCT-125 Drug Info [88]
MDL-28618 Drug Info [60]
METHYLENEDIOXYAMPHETAMINE Drug Info [111]
METHYLENEDIOXYMETHAMPHETAMINE Drug Info [81]
Milnacipran Drug Info [112]
N,N-dimethyl(2-phenoxyphenyl)methanamine Drug Info [113]
N-(2-oxazolemethyl)milnacipran Drug Info [114]
N-benzyl-N-isobutylpiperidin-4-amine Drug Info [108]
N-desalkylquetiapine Drug Info [115]
NISOXETINE Drug Info [116]
norzotepine Drug Info [117]
NS 2359 Drug Info [118]
Para-chloroamphetamine Drug Info [81]
PF-18298 Drug Info [64]
PF-3409409 Drug Info [119]
PF-526014 Drug Info [64]
Phenmetrazine Drug Info [120]
Phentermine Drug Info [121]
POLYGALATENOSIDE B Drug Info [122]
Protriptyline Drug Info [123]
PTI-601 Drug Info [88]
PYROVALERONE Drug Info [73]
R-NORDULOXETINE Drug Info [65]
Radafaxine Drug Info [124], [56]
Radaxafine HCl Drug Info [36]
Reboxetine Drug Info [125]
RG-7166 Drug Info [126]
RTI-219 Drug Info [127]
S-34324 Drug Info [128]
S33005 Drug Info [129]
SPD-473 Drug Info [130]
Trans-3-(o-tolyloxy)-2,3-dihydro-1H-inden-1-amine Drug Info [96]
Trimipramine Drug Info [131]
Ultracet Drug Info [100]
Venlafaxine Drug Info [95]
WAY-256805 Drug Info [132]
WIN-35065-2 Drug Info [133]
WIN-35066-2 Drug Info [134]
WIN_35428 Drug Info [133]
XEN-2174 Drug Info [135]
[3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine Drug Info [74]
[3H]mazindol Drug Info [136]
[3H]nisoxetine Drug Info [88]
{2-[3-(Phenylsulfonyl)-1H-indol-4-yl]ethyl}amine Drug Info [137]
Enhancer 18F-LMI-1195 Drug Info [138]
Modulator 3,4-Methylenedioxymethamphetamine Drug Info [139]
Bicifadine Drug Info
BL-1021 Drug Info
Iobenguane I-123 - GE Healthcare Drug Info [17]
Levomilnacipran Drug Info [18]
Manifaxine Drug Info [140]
Mazindol Drug Info [141]
Metaiodobenzylguanidine I-131 Drug Info [142]
MMDA Drug Info [143]
Napitane mesilate Drug Info
NS-2389 Drug Info [144]
R-sibutramine metabolite Drug Info
Rhopressa Drug Info [46]
Roclatan Drug Info [145]
Sibutramine Drug Info [141]
Suronacrine maleate Drug Info
Tapentadol hydrochloride Drug Info [17]
TD-9855 Drug Info [47]
Blocker Esreboxetine Drug Info [146]
Activator NSD-644 Drug Info [147]
Agonist TQ-1017 Drug Info [4]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
PANTHER Pathway Adrenaline and noradrenaline biosynthesis
Reactome Na+/Cl- dependent neurotransmitter transporters
WikiPathways Monoamine Transport
NRF2 pathway
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
References
REF 1Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
REF 2Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39.
REF 3(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 200).
REF 4Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
REF 5FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 072688.
REF 6(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 201).
REF 7Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci. 2008 Apr;29(4):208-17. Epub 2008 Mar 18.
REF 8(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7118).
REF 9(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2286).
REF 10Drug information of Cocaine, 2008. eduDrugs.
REF 11(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2399).
REF 12Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
REF 13(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7161).
REF 14(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 202).
REF 15(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 357).
REF 16ClinicalTrials.gov (NCT01936649) Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.. U.S. National Institutes of Health.
REF 172008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
REF 18Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
REF 19(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7435).
REF 20(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4797).
REF 21Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. Endocrine. 2000 Oct;13(2):193-9.
REF 22Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. Epub 2008 Jan 2.
REF 23(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7436).
REF 24Drug information of Phenmetrazine, 2008. eduDrugs.
REF 25Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
REF 26(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7269).
REF 27(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7285).
REF 28(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4808).
REF 29(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2586).
REF 30The Diversion of Ultram, Ultracet, and generic tramadol HCL. J Addict Dis. 2006;25(2):53-8.
REF 31Desvenlafaxine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2009;5:127-36. Epub 2009 Apr 8.
REF 32(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7321).
REF 33ClinicalTrials.gov (NCT00557427) Hypericum vs Fluoxetine for Mild to Moderate Adolescent Depression. U.S. National Institutes of Health.
REF 34J Clin Pharmacol. 2004 Dec;44(12):1360-7.DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile.
REF 35Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor. CNS Drug Rev. 2006 Summer;12(2):123-34.
REF 36Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
REF 37A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013 May;21(5):935-43.
REF 38ClinicalTrials.gov (NCT02276209) Dasotraline Adult ADHD Study. U.S. National Institutes of Health.
REF 39(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8308).
REF 40ClinicalTrials.gov (NCT02558400) Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension.
REF 41Handbook of Dementing Illnesses, Morris John. Page(570).
REF 42ClinicalTrials.gov (NCT01085175) Trial to Determine Imaging Parameters of LMI1195 in Heart Failure Patients at Low and High Risk of Defibrillator Firing. U.S. National Institutes of Health.
REF 43Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022855)
REF 44Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004852)
REF 45ClinicalTrials.gov (NCT00353938) Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder. U.S. National Institutes of Health.
REF 46Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4.
REF 47Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18(2). pii: pyu027.
REF 48Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021315)
REF 49ClinicalTrials.gov (NCT01121380) A Study Intended to Evaluate Safety, Tolerability and Pharmacokinetics (PK) Parameters of BL-1021. U.S. National Institutes of Health.
REF 50ClinicalTrials.gov (NCT01153802) An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy,Pharmacokinetics and Safety of Single Oral Dosesof GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands. U.S. National Institutes of Health.
REF 51Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040151)
REF 52Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder. Drug Des Devel Ther. 2014 Dec 1;8:2321-32.
REF 53Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006906)
REF 54Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005107)
REF 55Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009012)
REF 56Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2006 Nov;11(4):621-34.
REF 57Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010517)
REF 58Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027571)
REF 59Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031598)
REF 60Bioorg Med Chem Lett. 2008 Aug 15;18(16):4495-8. Epub 2008 Jul 17.Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.
REF 61Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. Epub 2009 Feb 20.Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.
REF 62J Med Chem. 2010 Jun 24;53(12):4731-48.Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.
REF 63Bioorg Med Chem Lett. 2006 Apr 1;16(7):2022-5. Epub 2006 Jan 18.Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter.
REF 64Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. Epub 2010 Apr 18.Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.
REF 65Bioorg Med Chem. 2009 Oct 1;17(19):6890-7. Epub 2009 Aug 20.Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents fordepression.
REF 66Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
REF 67Bioorg Med Chem. 2009 Jan 1;17(1):337-43. Epub 2008 Nov 5.Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.
REF 68Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. Epub 2006 Jun 5.N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.
REF 69Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53. Epub 2006 Jun 5.Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.
REF 70J Med Chem. 1986 Aug;29(8):1406-12.Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-aminoethyl)-2,3-dihydroindoles.
REF 71Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
REF 72Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. Epub 2009 Dec 6.Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
REF 73J Med Chem. 2006 Feb 23;49(4):1420-32.1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.
REF 74J Med Chem. 2004 May 6;47(10):2624-34.Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters.
REF 75Bioorg Med Chem Lett. 2010 Sep 15;20(18):5567-71. Epub 2010 Aug 17.Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.
REF 76J Med Chem. 2010 Mar 11;53(5):2204-14.Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.
REF 77J Med Chem. 2008 Nov 27;51(22):7265-72.Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
REF 78Bioorg Med Chem Lett. 2007 Jan 15;17(2):533-7. Epub 2006 Oct 12.Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER.
REF 79Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. Epub 2009 Jan 15.2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.
REF 80J Med Chem. 2009 Nov 12;52(21):6768-81.Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.
REF 81Eur J Med Chem. 2009 Dec;44(12):4862-88. Epub 2009 Aug 6.Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents.
REF 82Bioorg Med Chem Lett. 2008 Dec 1;18(23):6067-70. Epub 2008 Oct 11.Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.
REF 83J Med Chem. 2007 Apr 19;50(8):1925-32. Epub 2007 Mar 17.Designing active template molecules by combining computational de novo design and human chemist's expertise.
REF 84Bioorg Med Chem Lett. 2000 Nov 6;10(21):2445-7.3alpha-(4-Substituted phenyl)nortropane-2beta-carboxylic acid methyl esters show selective binding at the norepinephrine transporter.
REF 85J Med Chem. 2006 Oct 19;49(21):6391-9.Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogues for in vivo investigation.
REF 86Bioorg Med Chem Lett. 2007 Jun 1;17(11):3099-104. Epub 2007 Mar 16.Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors.
REF 87J Med Chem. 2010 Sep 9;53(17):6386-97.Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.
REF 88(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926).
REF 89Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
REF 90A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):285-90.
REF 91Effects of acute and chronic treatment with amoxapine and cericlamine on the sleep-wakefulness cycle in the rat. Neuropharmacology. 1994 Aug;33(8):1017-25.
REF 92New drugs for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2004 Nov;9(2):293-302.
REF 93Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl). 2008 Sep;200(1):39-50. Epub 2008 Jun 22.
REF 94Bioorg Med Chem Lett. 2008 Aug 1;18(15):4355-9. Epub 2008 Jun 25.Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.
REF 95Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
REF 96Bioorg Med Chem Lett. 2008 Jul 15;18(14):4224-7. Epub 2008 May 20.Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).
REF 97Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81. Epub 2009 Apr 17.
REF 98Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. Epub 2008 Jan 11.Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an exocyclic hydroxyl group: interaction with dopamine, serotonin, and norepinephrine transporters.
REF 99Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
REF 100Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Jun 11.
REF 101Phentermine and anaesthesia. Anaesth Intensive Care. 2005 Aug;33(4):525-7.
REF 102Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. Epub 2006 Nov 28.
REF 103Duloxetine for the treatment of generalized anxiety disorder: a review. Neuropsychiatr Dis Treat. 2009;5:23-31. Epub 2009 Apr 8.
REF 104Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther. 2013 Aug;346(2):311-7.
REF 105The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Mol Psychiatry. 1999 Jul;4(4):333-8.
REF 106Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol. 1999 Mar 5;368(2-3):277-83.
REF 107Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8. Epub 2008 Nov 30.
REF 108Bioorg Med Chem Lett. 2006 May 15;16(10):2714-8. Epub 2006 Feb 23.N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.
REF 109Antimicrob Agents Chemother. 2007 Nov;51(11):4133-40. Epub 2007 Sep 10.Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.
REF 110Effect of pharmacologically selective antidepressants on serotonin uptake in rat platelets. Gen Physiol Biophys. 2005 Mar;24(1):113-28.
REF 111Bioorg Med Chem. 2010 Jun 1;18(11):4009-31. Epub 2010 Apr 13.Synthesis and in vitro toxicity of 4-MTA, its characteristic clandestine synthesis byproducts and related sulfur substituted alpha-alkylthioamphetamines.
REF 112Milnacipran: Beyond a Role of Antidepressant. Clin Neuropharmacol. 2009 Jun 10.
REF 113Bioorg Med Chem Lett. 2008 Jan 15;18(2):596-9.1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.
REF 114Bioorg Med Chem Lett. 2008 Feb 15;18(4):1346-9. Epub 2008 Jan 9.Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.
REF 115N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2008 Sep;33(10):2303-12. Epub 2007 Dec 5.
REF 116Bioorg Med Chem Lett. 2008 Sep 15;18(18):4929-31. Epub 2008 Aug 22.Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.
REF 117Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake. J Pharmacol Exp Ther. 2010 Jun;333(3):772-81.
REF 118Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34.
REF 119Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83. Epub 2009 Jul 2.Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.
REF 120Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
REF 121Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.
REF 122J Nat Prod. 2006 Sep;69(9):1305-9.Antidepressant principles of the roots of Polygala tenuifolia.
REF 123Analgesic properties of intrathecally administered heterocyclic antidepressants. Pain. 1987 Mar;28(3):343-55.
REF 124Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
REF 125Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82.
REF 126Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031598)
REF 127J Med Chem. 2007 Jul 26;50(15):3686-95. Epub 2007 Jun 30.Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2beta-[5-(substituted phenyl)thiazol-2-yl]tropanes.
REF 128J Med Chem. 2005 Mar 24;48(6):2054-71.Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity.
REF 129Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23.
REF 130Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors. J Pharmacol Exp Ther. 2005 Mar;312(3):1124-31. Epub 2004 Nov 12.
REF 131Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90. Epub 2006 Jan 4.
REF 132J Med Chem. 2008 Jul 10;51(13):4038-49. Epub 2008 Jun 17.Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.
REF 133J Med Chem. 1996 Oct 11;39(21):4139-41.3 alpha-(4'-substituted phenyl)tropane-2 beta-carboxylic acid methyl esters: novel ligands with high affinity and selectivity at the dopamine transporter.
REF 134J Med Chem. 2004 Dec 2;47(25):6401-9.Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers.
REF 135Spinal noradrenaline transporter inhibition by reboxetine and Xen2174 reduces tactile hypersensitivity after surgery in rats. Pain. 2005 Feb;113(3):271-6.
REF 136Binding of [3H]mazindol to cardiac norepinephrine transporters: kinetic and equilibrium studies. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):9-16. Epub 2004 Jul 22.
REF 137Bioorg Med Chem. 2009 Nov 15;17(22):7802-15. Epub 2009 Sep 18.Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.
REF 138Assessment of the 18F-labeled PET tracer LMI1195 for imaging norepinephrine handling in rat hearts. J Nucl Med. 2013 Jul;54(7):1142-6.
REF 139The origin of <span class="caps">MDMA</span> (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5.
REF 140Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects. Pharmacogenet Genomics. 2005 Dec;15(12):883-9.
REF 141Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
REF 142Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res. 2014 Apr 15;20(8):2182-91.
REF 143How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
REF 144Clinical pipeline report, company report or official report of Neurosearch.
REF 145Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
REF 146Pfizer. Product Development Pipeline. March 31 2009.
REF 147Clinical pipeline report, company report or official report of Neurosearch.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.